» Articles » PMID: 28186987

BRCA1 P.His1673del is a Pathogenic Mutation Associated with a Predominant Ovarian Cancer Phenotype

Abstract

We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer.The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor.The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.

Citing Articles

Clinical genetic services in the Emilia-Romagna region, Italy: current activity and open issues: a mixed-method study.

Godino L, Ambrosini E, Barili V, Graziano C, Garavelli L, Calabrese O J Community Genet. 2025; .

PMID: 39797934 DOI: 10.1007/s12687-024-00750-7.


Molecular analysis of BRCA1 and BRCA2 genes in La Rioja (Spain): five new variants.

Salazar Saez R, Zorrilla M, Sanchez R, Cebollero A, Manrique I, Martin A Hered Cancer Clin Pract. 2024; 22(1):22.

PMID: 39438962 PMC: 11495111. DOI: 10.1186/s13053-024-00296-2.


Atypical cancer risk profile in carriers of Italian founder BRCA1 variant p.His1673del: Implications for classification and clinical management.

Innella G, Fortuno C, Caleca L, Feng B, Carroll C, Parsons M Cancer Med. 2024; 13(16):e70114.

PMID: 39194334 PMC: 11350839. DOI: 10.1002/cam4.70114.


Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result in Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay.

Concolino P, De Paolis E, Rinelli M, Maneri G, Brisighelli F, Trozzi R Ann Lab Med. 2024; 44(6):617-620.

PMID: 38826062 PMC: 11375183. DOI: 10.3343/alm.2024.0051.


The emergence of Fanconi anaemia type S: a phenotypic spectrum of biallelic mutations.

Hughes T, Rose A Front Oncol. 2023; 13:1278004.

PMID: 38146508 PMC: 10749362. DOI: 10.3389/fonc.2023.1278004.


References
1.
Chenevix-Trench G, Healey S, Lakhani S, Waring P, Cummings M, Brinkworth R . Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res. 2006; 66(4):2019-27. DOI: 10.1158/0008-5472.CAN-05-3546. View

2.
Tavtigian S, Deffenbaugh A, Yin L, Judkins T, Scholl T, Samollow P . Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2005; 43(4):295-305. PMC: 2563222. DOI: 10.1136/jmg.2005.033878. View

3.
Lakhani S, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S . Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004; 10(7):2473-81. DOI: 10.1158/1078-0432.ccr-1029-3. View

4.
Giunchi F, Fiorentino M, Vagnoni V, Capizzi E, Bertolo R, Porpiglia F . Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients. Pathology. 2016; 48(1):41-6. DOI: 10.1016/j.pathol.2015.11.009. View

5.
Turkovic L, Gurrin L, Bahlo M, Dite G, Southey M, Hopper J . Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age. BMC Cancer. 2010; 10:466. PMC: 2940805. DOI: 10.1186/1471-2407-10-466. View